Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Net cash floor.
ACCE opinionBIO-key International Inc. Common Stock (BKYI)
Fair value
Not available
ACCE price target
$2.50
Rating
Not rated
Horizon
12 months
ACCE price target published on 23 Oct 2026, 01:53 CEST; previously $2.30 since 22 Oct 2026, 01:52 CEST.
Price used: $3.39 at the close on 23 Oct 2026, 22:00 CEST.
Models: Net cash floor.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
36
out of 100
Analysts
100% buy
1 covering
P/E
0.0x
forward 0.0x
1-year return
-55.4%
Dividend yield
0.00%
BIO-key International Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
BIO-key International sells biometric identity software, including its PortalGuard identity and access management platform and fingerprint-based authentication tools for enterprise and government customers. The appeal is the business model: an 81.3% gross margin means most incremental revenue drops to the gross profit line, and the company is growing top-line revenue at 13.1%. The case rests on whether that revenue growth can close a gap that is still wide, since the operating margin sits at -27.6% and return on equity at -107.9% reflects continuing losses. At a market cap of about $6M and a score of 32/100, this is a micro-cap that is not in any major index and carries real execution and financing risk, so it earns a look only if you believe operating leverage can arrive before the balance sheet forces the issue.